Lv51
810 积分 2022-11-14 加入
Disitamab Vedotin Alone or in Combination With Immune Checkpoint Inhibitors in Bladder-Sparing Treatment of Muscle-Invasive Bladder Cancer: A Real-World Study
19天前
已完结
A clinical study of RC48-ADC combined with PD-1 inhibitor in bladder preservation therapy for muscle-invasive bladder cancer (MIBC)-based on real-world data analysis
19天前
已完结
Bladder preservation with disitamab vedotin plus PD-1 inhibitors and local intensification in muscle-invasive bladder cancer: a single-center retrospective cohort of 81 patients
19天前
已完结
Efficacy and Safety of Disitamab Vedotin Combined with Gemcitabine as Neoadjuvant Therapy in Muscle-invasive Bladder Cancer: An Open-label, Multicenter, Single-arm, Phase 2 Trial
19天前
已完结
Efficacy and biomarker analysis of neoadjuvant disitamab vedotin (RC48-ADC) combined immunotherapy in patients with muscle-invasive bladder cancer: A multi-center real-world study
19天前
已完结
PROTEUS Trial the Day After: Practice Changing or Premature Escalation?
22天前
已完结
Fruquintinib Plus Sintilimab in Patients with Treatment-Naive and Previously Treated Advanced Renal Cell Carcinoma: Results from a Phase Ib/II Clinical Trial
1个月前
已完结
Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study
1个月前
已完结
[(177)Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial
1个月前
已完结
皖公网安备34019202002308
